Curasight is focused on addressing the need for improved diagnose of Prostate cancer and building on its foundation of pioneering research and development within uPAR-PET Imaging.

Our clinical development efforts include a program to develop a first-in-class uPAR-PET imaging ligand which is currently entering phase II. We believe that our uPAR-PET ligands have the potential to provide physicians with improved non-invasive and cost-effective options to help diagnose and evaluate prostate cancer disease